Chinese Journal of Clinical Anatomy >
Expression of IL-6 and PRL in breast cancer tissue and its clinical significance
Received date: 2018-03-23
Online published: 2018-07-04
Objective To investigate the expression of interleukin-6 (IL-6) and prolactin (PRL) in breast invasive ductal carcinoma (BIDC) and its clinical significance. Method Immunohistochemistry was used to detect the expression of IL-6 and PRL in 63 cases of breast cancer and its paraneoplastic tissues and 17 cases of breast fibroadenoma. The clinical pathological parameters and event-free survival were analyzed statistically. Results The positive rates of IL-6 and PRL in infiltrating ductal carcinoma were higher than those in adjacent tissues and fibroids (P<0.05). The expressions of IL-6 and PRL in the adjacent tissues were higher than those in paratumor tissues (P<0.05). The expression of IL-6 and PRL were correlated with tumor size and TNM stage (P<0.05). There was a significant positive correlation between IL-6 and PRL expression (rs= 0.842, P<0.05). Event-free survival showed that the event-free survival of patients with high expression of IL-6 and PRL was lower than that of patients with low expression (IL-6, Log- rank= 5.186, P= 0.023; PRL, Log- rank= 5.743, respectively. P= 0.017). The univariate Cox risk model showed that lymph node metastasis, high TNM stage, positive IL-6 expression, and positive PRL expression all had influence on the event-free survival of patients. Conclusion The detection of PRL and IL-6 expression in breast cancer is beneficial to its prognosis diagnosis; Reducing the patient's stress, promoting emotional regulation, improving sleep quality and other factors can, to some extent, reduce the risk of breast cancer, progression and poor prognosis.
Key words： ; Breast tumor; IL-6; Prolactin; Immunohistochemistry; Prognosis
GAO Yan-xin , SUN Jing-bo , DENG Yun-yao , LIU Li-xin , LIU Xiao-long . Expression of IL-6 and PRL in breast cancer tissue and its clinical significance[J]. Chinese Journal of Clinical Anatomy, 2018 , 36(3) : 288 -293 . DOI: 10.13418/j.issn.1001-165x.2018.03.010
[1] DeSantis CE, Bray F, Ferlay J, et al. International variation in female breast cancer incidence and mortality rates[J]. Cancer Epidemiol Biomarkers Prev, 2015, 24(10): 1495-1506.
[2] Zeng H, Zheng R, Guo Y, et al. Cancer survival in China, 2003-2005: a population-based study[J]. Int J Cancer, 2015, 136(8): 1921-1930.
[3] Felipe LJ, Nofech-Mozes S, Bayani J, et al. EMT in breast carcinoma-a review[J]. J Clin Med, 2016, 5(7): E65.
[4] Sullivan NJ, Sasser AK, Axel AE, et al. Interleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells[J]. Oncogene, 2009, 28(33): 2940-2947.
[5] Fizazi K, De Bono JS, Flechon A, et al. Randomised phase II study of siltuximab (CNTO 328), an anti-IL-6 monoclonal antibody, in combination with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer[J]. Eur J Cancer, 2012, 48(1): 85-93.
[6] Olsen J, Kirkeby LT, Olsen J, et al. High interleukin-6 mRNA expression is a predictor of relapse in colon cancer[J]. Anticancer Res, 2015, 35(4): 2235-2240.
[7] Sasser AK, Sullivan NJ, Studebaker AW, et al. Interleukin-6 is a potent growth factor for ER-alpha-positive human breast cancer[J]. FASEB J, 2007, 21(13): 3763-3770.
[8] Clevenger CV, Furth PA, Hankinson SE, et al. The role of prolactin in mammary carcinoma[J]. Endocr Rev, 2003, 24(1): 1-27.
[9] Shiu RP, Murphy LC, Tsuyuki D, et al. Biological actions of prolactin in human breast cancer[J]. Recent Prog Horm Res, 1987, 43: 277-303.
[10]Binart N, Ormandy CJ, Kelly PA. Mammary gland development and the prolactin receptor[J]. Adv Exp Med Biol, 2000, 480: 85-92.
[11] 王庭槐.生理学[M].第3版, 北京：人民卫生出版社, 2015: 555.
[12] Blanco EJ, Carretero-Hernández M, García-Barrado J, et al. The activity and proliferation of pituitary prolactin-positive cells and pituitary VIP-positive cells are regulated by interleukin 6[J]. Histol Histopathol, 2013, 28(12): 1595-1604.
[13] Amin MB, Edge S, Greene FL. AJCC cancer staging manual[M]. 8th ed. New York: Springer, 2016.
[14] Hirano T, Yasukawa K, Harada H, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin[J]. Nature, 1986, 324(6092): 73-76.
[15] De Filippo G, Rendina D, Moccia F, et al. Interleukin-6, soluble interleukin-6 receptor/interleukin-6 complex and insulin resistance in obese children and adolescents[J]. J Endocrinol Invest, 2015, 38(3): 339-343.
[16]Chen X, Wang L, Wang W, et al. B7-H4 facilitates proliferation of esophageal squamous cell carcinoma cells through promoting interleukin-6/signal transducer and activator of transcription 3 pathway activation[J]. Cancer Sci, 2016, 107(7): 944-954.
[17]Li F, Gu C, Tian F, et al. MiR-218 impedes IL-6-induced prostate cancer cell proliferation and invasion via suppression of LGR4 expression[J]. Oncol Rep, 2016, 35(5): 2859-2865.
[18]Rokavec M, Öner MG, Li H, et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis[J]. J Clin Invest, 2014, 124(4): 1853-1867.
[19]Jiang Q, Li Q, Chen H, et al. Scutellaria barbata D. Don inhibits growth and induces apoptosis by suppressing IL-6-inducible STAT3 pathway activation in human colorectal cancer cells[J]. Exp Ther Med, 2015, 10(4): 1602-1608.
/
| 〈 |
|
〉 |
